Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Impact · against what's priced in

The enrollment of the first patient in the bexobrutideg combination study is a positive operational milestone for Nurix and Roche, though it is an early-stage event. The move toward combination therapy in CLL expands the potential utility of the asset beyond the current head-to-head trials against pirtobrutinib.

NRIX+0.30

No priced-in read yet